- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00750256
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1278863A in Healthy Subjects
July 19, 2017 updated by: GlaxoSmithKline
A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects
A first-time in human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1278863A in healthy subjects
Study Overview
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Indiana
-
Evansville, Indiana, United States, 47710
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy, non-smoking (within 40 days of screening), adult males and females between 18 and 55 years of age, inclusive
- Female subjects are eligible for participation in the study if they are of:
- Non-childbearing potential (i.e., physiologically incapable of becoming pregnant);
- Male subjects agree to use contraception methods
- Body weight > or = 50 kg; BMI: 19-31 kg/m2, inclusive
- Subject has a QTc <450 msec or <480 msec if associated with bundle branch block
- Subject is willing and able to provide written informed consent
Exclusion Criteria:
- MCV value outside the reference range at screening
- Hemoglobin value at screening is: male subjects or post-menopausal females > 15.5 g/dL; female subjects > 14.5 g/dL
- TIBC, serum iron and serum ferritin values are outside the reference range at screening
- Calculated creatinine clearance < 60 ml/min
- Clinically significant abnormal CPK determined by the investigator and medical monitor
- AST, ALT and direct bilirubin are greater than upper limit of reference range at screening
- Subjects are unwilling or inability to follow the procedures and lifestyle and/or dietary restrictions outlined in the protocol
- Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor this will not interfere with the study procedures or compromise subject safety
- Subject currently exposures to more than four new chemical entities within 12 months prior to the first dosing day
- Use of other prescription or non-prescription drugs, vitamins, herbal and dietary supplements, within 7 days prior to the first dose of study medication
- Subject has a history of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy
- Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study drugs.
- Subject has a history of GI ulceration or gastrointestinal bleeding
- Subject has a history of peptic ulcer disease
- Subject has a history of malignancy tumor; non-melanoma skin cancer that has been definitely removed is allowed
- Treatment with an investigational drug within 30 days preceding the first dose of study medication
- Subjects with a history of drug abuse
- History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening
- Positive urine drug screen (UDS) at screening
- Positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result or positive HIV result within 3 months of screening
- Donation of blood in excess of 500 mL within 56 days prior to first dose of study medication
- Subject has a history of regular use of tobacco- or nicotine containing products
- History of sensitivity to heparin, heparin-induced thrombocytopenia or sensitivity to any of the study medications or components thereof
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohorts
This study will be a single-blind, randomized, placebo-controlled, dose-rising, single dose, parallel group study with 6 proposed Cohorts from 2mg to 450mg.
|
GSK1278863A planned doses from 2mg to 450mg which may change based on safety or PK from previous cohorts.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
GSK1278863A safety endpoints: adverse events reporting, clinical safety laboratory tests (hematology, chemistry, urinalysis,and fecal occult blood), vital signs, 12-lead ECG, dual-lead cardiac monitoring.
Time Frame: 1 Day
|
1 Day
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Blood and urine levels of GSK1278863A
Time Frame: 2 Days
|
2 Days
|
Effect of GSK1278863A on hematological markers
Time Frame: 2 Days
|
2 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 7, 2008
Primary Completion (Actual)
December 12, 2008
Study Completion (Actual)
December 12, 2008
Study Registration Dates
First Submitted
September 9, 2008
First Submitted That Met QC Criteria
September 9, 2008
First Posted (Estimate)
September 10, 2008
Study Record Updates
Last Update Posted (Actual)
July 21, 2017
Last Update Submitted That Met QC Criteria
July 19, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- PHX111427
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anaemia
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
International Centre for Diarrhoeal Disease Research...Completed
-
Daiichi Sankyo, Inc.Completed
-
GlaxoSmithKlineCompleted
-
Indian Council of Medical ResearchDelhi UniversityUnknown
-
Wageningen UniversityKenya Medical Research Institute; Akzo Nobel; Unilever Food and Health Research...Completed
Clinical Trials on GSK1278863A
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedKidney DiseaseNew Zealand